MCID: HYP073
MIFTS: 51

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 15
Immunoproliferative Disorders 45 74
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
MeSH 45 D007160
SNOMED-CT 69 86295000
ICD10 34 C88 C88.9
UMLS 74 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

Disease Ontology : 12 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response.

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to autoimmune lymphoproliferative syndrome and sarcoidosis 1. An important gene associated with Hypersensitivity Reaction Type Iv Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Doxorubicin and Daunorubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 autoimmune lymphoproliferative syndrome 31.9 CASP10 FAS FASLG IL2
2 sarcoidosis 1 31.7 ACE BTNL2 IL2 NOD2 TNF TNFRSF1B
3 heavy chain disease 11.3
4 cryoglobulinemia 11.3
5 schnitzler syndrome 11.3
6 chronic nk-cell lymphocytosis 11.3
7 lymphoid interstitial pneumonia 11.3
8 uveoparotid fever 10.4 ACE TNF
9 rectum squamous cell carcinoma 10.4 SMUG1 TNFRSF1B
10 subacute cutaneous lupus erythematosus 10.4 ACE TNF
11 anthracosilicosis 10.4 ACE SMUG1
12 inflammatory bowel disease 20 10.4 MRAP NOD2
13 oral tuberculosis 10.4 IL2 TNF
14 splenic tuberculosis 10.4 IL2 SMUG1
15 skin sarcoidosis 10.3 ACE TNF TNFRSF1B
16 orofacial granulomatosis 10.3 BTNL2 NOD2 TNF
17 posterior scleritis 10.3 MRAP TNF
18 cogan syndrome 10.3 SMUG1 TNF TNFRSF1B
19 ileocolitis 10.3 NOD2 TNF
20 vascular dementia 10.3 ACE SERPINA3 TNF
21 chronic gonococcal salpingitis 10.3 TNF TNFRSF1B
22 aortitis 10.3 MRAP SMUG1
23 kashin-beck disease 10.3 FAS TNF
24 streptococcal toxic-shock syndrome 10.3 IL2 TNF
25 acute salpingitis 10.3 MRAP TNF TNFRSF1B
26 lymphangiosarcoma 10.3 IL2 SMUG1 TNF
27 autoimmune lymphoproliferative syndrome, type iii 10.3 CASP10 FASLG
28 commensal bacterial infectious disease 10.3 BTNL2 IL2 TNF
29 panuveitis 10.3 MRAP TNF TNFRSF1B
30 lymphatic system disease 10.3 IL2 SMUG1 TNF
31 palindromic rheumatism 10.2 MRAP TNF TNFRSF1B
32 pulmonary sarcoidosis 10.2 ACE IL2 TNF
33 chronic venous leg ulcers 10.2 FAS FASLG
34 crohn's colitis 10.2 IL2 NOD2 TNF
35 type ii mixed cryoglobulinemia 10.2 FAS FASLG
36 leukocyte disease 10.2 IL2 SMUG1 TNF
37 chondromalacia 10.2 IL1RN SMUG1 TNFRSF1B
38 leprosy 3 10.2 IL2 NOD2 TNF
39 lymphocytic gastritis 10.2 FAS FASLG
40 coccidiosis 10.2 IL2 MRAP TNF
41 chagas disease 10.2 ACE IL2 TNF
42 urinary system disease 10.2 ACE IL2 TNF
43 granulomatous dermatitis 10.2 ACE NOD2 TNF TNFRSF1B
44 melkersson-rosenthal syndrome 10.2 ACE NOD2 TNF TNFRSF1B
45 epstein-barr virus-associated gastric carcinoma 10.2 FAS FASLG TNF
46 primary bacterial infectious disease 10.2 IL2 TNF TNFRSF1B
47 respiratory failure 10.2 ACE ALPL TNF
48 waldenstrom macroglobulinemia 10.2
49 alpha-heavy chain disease 10.2
50 pouchitis 10.2 IL1RN NOD2

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 ACE FAS IL2 NOD2 TNF TNFRSF1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 ACE FAS FASLG IL2 NOD2 TNF

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 ALPI ALPL FAS FASLG IL2 NOD2
2 hematopoietic system MP:0005397 9.85 ACE ALPL CCR6 FAS FASLG IL1RN
3 homeostasis/metabolism MP:0005376 9.73 ACE ALPI ALPL CCR6 FAS FASLG
4 neoplasm MP:0002006 9.17 ACE FAS FASLG IL2 SMUG1 TNF

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1068)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
4
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
6
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
11
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
12
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
15
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
17
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
19
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
20
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
21
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
22
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
23
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
24
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
25
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
26
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
27
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
28
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
29
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
30
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
31
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
32
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
33
Ferrous succinate Approved Phase 4 10030-90-7
34
Iron Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
35
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 11953898 15589840
36
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
37
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 6857599 5310940 9887054 43805
38
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
39
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
40
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
41
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 460612 4053
42
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
43
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
44
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
45
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53910-25-1 40926 439693
46
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
47
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
48
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
49
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177 70789204
50
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 8325)
# Name Status NCT ID Phase Drugs
1 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
2 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
3 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
4 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
5 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
6 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
8 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
11 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
12 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
13 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
14 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
15 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
16 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
17 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
18 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
19 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
20 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
21 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
22 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
23 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
24 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
25 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
26 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
27 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
28 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
29 A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies Completed NCT00776425 Phase 4 Epoetin beta
30 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
31 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
32 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
33 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
34 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
35 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
36 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
37 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
38 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
39 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
40 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
41 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
42 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
43 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
44 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
45 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
46 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
47 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
48 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
49 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
50 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

42
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Breast

Publications for Hypersensitivity Reaction Type Iv Disease

Articles related to Hypersensitivity Reaction Type Iv Disease:

(show all 11)
# Title Authors Year
1
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. ( 23161721 )
2012
2
Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. ( 14652716 )
2004
3
Effect of alpha IFN on unaggressive immunoproliferative disorders. ( 7758989 )
1995
4
Atypical immunoproliferative disorders: when of age? ( 8506619 )
1993
5
Structurally abnormal immunoglobulins in human immunoproliferative disorders. ( 1571535 )
1992
6
Immunoproliferative disorders: detection, prevention, and therapeutics. ( 2508454 )
1989
7
Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. ( 6667410 )
1983
8
Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. ( 4216270 )
1974
9
Surface IgD in immunoproliferative disorders. ( 4218365 )
1974
10
Lymphocyte transformation in immunoproliferative disorders. ( 4114813 )
1972
11
M-components in immunoproliferative disorders. Electrophoretic and immunologic analysis of 200 cases. ( 4964131 )
1967

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 BTNL2 CASP10 CCR6 FASLG IFNA1 IL1RN
2
Show member pathways
13.59 CASP10 CCR6 FAS FASLG IFNA1 IL1RN
3
Show member pathways
13.3 FASLG IFNA1 IL1RN IL2 NOD2 TNF
4
Show member pathways
13.21 CASP10 CCR6 FAS FASLG IL2 TNF
5
Show member pathways
12.97 ACE FAS FASLG IFNA1 IL2 NOD2
6
Show member pathways
12.88 CASP10 FAS FASLG IFNA1 TNF TNFRSF1B
7
Show member pathways
12.74 CASP10 FAS FASLG TNF TNFRSF1B
8
Show member pathways
12.73 FAS FASLG IFNA1 IL2 TNF TNFRSF1B
9
Show member pathways
12.51 FAS FASLG IFNA1 IL2 TNF
10
Show member pathways
12.51 CASP10 FAS FASLG TNF TNFRSF1B
11
Show member pathways
12.33 FAS FASLG IFNA1 IL2 TNF
12
Show member pathways
12.29 CASP10 FAS FASLG TNF TNFRSF1B
13
Show member pathways
12.18 CASP10 FAS FASLG TNF
14 12.14 FAS FASLG TNF TNFRSF1B
15 12.11 CASP10 IFNA1 NOD2 TNF
16
Show member pathways
12.1 CASP10 FAS FASLG TNF TNFRSF1B
17
Show member pathways
12.09 ALPG ALPI ALPL ALPP
18
Show member pathways
12.08 FAS FASLG IFNA1 TNF
19 12.01 FAS FASLG IFNA1 IL1RN IL2 TNF
20
Show member pathways
11.82 ALPG ALPI ALPL
21 11.71 CCR6 IL2 TNF
22 11.7 CASP10 FAS NOD2 TNF TNFRSF1B
23
Show member pathways
11.67 FASLG IL2 TNF
24 11.64 IL1RN IL2 TNF
25
Show member pathways
11.54 FASLG IL2 TNF
26 11.39 IL1RN TNF TNFRSF1B
27 11.33 FAS FASLG IL2 TNF
28 11.31 FAS FASLG TNF
29 11.22 FAS FASLG TNF
30
Show member pathways
10.92 ALPG ALPI ALPL ALPP
31 10.13 ALPG ALPI ALPL ALPP

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 ACE ALPG ALPI ALPL ALPP BTNL2
2 cell surface GO:0009986 9.73 ALPP CCR6 FAS FASLG NOD2 TNF
3 external side of plasma membrane GO:0009897 9.72 ACE BTNL2 CCR6 FASLG TNF
4 membrane raft GO:0045121 9.71 FAS FASLG TNF TNFRSF1B
5 anchored component of membrane GO:0031225 9.46 ALPG ALPI ALPL ALPP
6 extracellular region GO:0005576 9.4 ACE ALPG ALPI ALPL FAS FASLG
7 CD95 death-inducing signaling complex GO:0031265 9.37 CASP10 FAS
8 extracellular space GO:0005615 10.03 ACE ALPL FASLG IFNA1 IL1RN IL2

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 FASLG IFNA1 IL1RN IL2 TNF
2 immune response GO:0006955 9.8 CCR6 FAS FASLG IL1RN IL2 TNF
3 dephosphorylation GO:0016311 9.78 ALPG ALPI ALPL ALPP
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.77 CASP10 FASLG IL1RN NOD2 TNF
5 cellular response to lipopolysaccharide GO:0071222 9.76 IL1RN NOD2 TNF TNFRSF1B
6 positive regulation of JNK cascade GO:0046330 9.74 IL1RN NOD2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.73 ALPL NOD2 TNF
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.72 FASLG TNF TNFRSF1B
9 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.71 CASP10 FAS FASLG TNF
10 response to glucocorticoid GO:0051384 9.7 ALPL IL1RN TNF
11 positive regulation of interleukin-6 production GO:0032755 9.69 IL1RN NOD2 TNF
12 humoral immune response GO:0006959 9.67 CCR6 IFNA1 TNF
13 cytokine-mediated signaling pathway GO:0019221 9.63 FASLG IFNA1 IL1RN IL2 TNF TNFRSF1B
14 apoptotic signaling pathway GO:0097190 9.62 CASP10 FAS FASLG TNF
15 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.6 FAS FASLG
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 TNF TNFRSF1B
17 maintenance of gastrointestinal epithelium GO:0030277 9.58 NOD2 SERPINA3
18 positive regulation of interleukin-17 production GO:0032740 9.58 IL2 NOD2
19 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG TNF TNFRSF1B
20 chronic inflammatory response to antigenic stimulus GO:0002439 9.13 TNF
21 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatase activity GO:0016791 9.46 ALPG ALPI ALPL ALPP
2 cytokine activity GO:0005125 9.35 FASLG IFNA1 IL1RN IL2 TNF
3 alkaline phosphatase activity GO:0004035 8.92 ALPG ALPI ALPL ALPP

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....